All In Biotech

Drug Trial Radar · NCT07504263

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Dec 1, 2027

Study completion Apr 1, 2028

Sponsor

Lead sponsor
Recurv Pharma IncIndustry
Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2a Study of RP-001 in participants with Advanced Malignancies

Conditions

  • Advanced Malignancies
  • Oncology
  • Colorectal Cancer
  • Pancreatic Cancer
  • Cancer

Interventions

  • RP-001Drug

    A new class of Taxane.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To characterize the safety and tolerability of RP-001 administered as monotherapy.Time frame: 1 month

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.